Though DPP-4is such as linagliptin do not possess the ability to cross the BBB, they are still proven to possess neuroprotective effects, especially in Alzheimer’s disease, by increasing the bioactivity of GLP-1, which is effective in penetrating the BBB [48]. This evidence concerns the gene GLP1R and early-onset autosomal dominant Alzheimer disease.